Avid Bioservices Inc (CDMO)

[jazzbeerman]

moby,


The Georgia phase 2 breast cancer trial is not completely enrolled.
The trial is for 46 patients.
There was never a press release saying it's completely enrolled.
You may be misunderstanding the Simon two-stage design of the trial.


please post any press release quotes you're referring to.

-------------------------

There has never been interim updates in ANY Bavituximab phase 1 trial.
Neither cancer, nor HCV Bavituximab phase 1 trials have ever issued interim data.

The 1st Bavituximab HCV trial did not.
The 2nd Bavituximab HCV trial did not.
The US cancer monotherapy trial has not.
The Indian cancer trial did not.

You will hear info when the trial is done, as has happened in every other phase 1 Bavituximab trial.


please post any interim data from these previous trials you are aware of.


------------------------


Pojen Chen is listed on PPHM's SAB.
He's not listed under "HIV", or HCV",
He's listed under "CORE TECHNOLOGIES".
Peregrine would not be paying the competition.
IS1 is Pojen Chen's.

I had figured Chen's mabs were a part of Peregrine Intellectual Property when I saw his name listed under Core Technologies, and Chen's mabs were being focussed on by Bart Haynes group, as reported several times in CHAVI/Gates literature.

Then I saw in the recent SEC report that Peregrine had licensed anti-PS mabs from Chen's university.

If you're looking for even more of a smoking gun, I think you'll have to wait for whatever paper comes out which details all the work done with Pojen Chen's (Peregrine's) IS1 mab.

and yes, of course there will be a paper all about it.

Haynes says in his recent patent application,

A method of treating HIV comprising administering to a patient in need thereof an antibody derivable from a normal subject or from an autoimmune disease subject that binds to a lipid on the surface of HIV or on the surface of HIV-infected cells and thereby neutralizes HIV-1, wherein said antibody is administered in an amount sufficient to effect said treatment.



The method according to claim 1 wherein said antibody is non-pathogenic.

The method according to claim 1 wherein said antibody is IS1, IS4 or IS6, or binding fragment thereof.

The method according to claim 1 wherein said antibody is IS1, or binding fragment thereof.



* IS1 is an antibody that can be safely used as a therapeutic Mab for treatment of HIV infected subjects

* these antibodies can broadly neutralize HIV in an unprecedented manner.

* reactivity with the HIV envelope is not a prerequisite for neutralization in these antibodies.


AND MY FAVORITE "broad implication" point mentioned by Haynes -

It will be appreciated from a reading of the foregoing that if HIV has evolved to escape the host immune response by making the immune system blind to it, other infectious agents may have evolved similarly. That is, this may represent a general mechanism of escape. That being the case, approaches comparable to those described herein can be expected to be useful in the treatment of such other agents well.


http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=2&p=1&f=G&l=50&d=PG01&S1=%28%22haynes+Barton%22.IN.%29&OS=in/%22haynes+Barton%22&RS=IN/%22haynes+Barton%22


----------


Obviously this is very important work, and no paper has yet been published on the work. But one will.

I think it'll turn some heads, and yes, I tihnk it will be reporting good things about PEREGRINE'S mabs as therapy for HIV.

King recently said the work has expanded, to 9 institutions and 50 scientists, which to me implies 'good' things.

As for clinical trials, if the data warrants it, (and Haynes patent application excerpts above sure seem like it!), I'd expect to see them happen at, and be run by Duke, likely sponsored by NIAID or the Gates.



j